NL1014636C2 - Vitaminepreparaat. - Google Patents
Vitaminepreparaat. Download PDFInfo
- Publication number
- NL1014636C2 NL1014636C2 NL1014636A NL1014636A NL1014636C2 NL 1014636 C2 NL1014636 C2 NL 1014636C2 NL 1014636 A NL1014636 A NL 1014636A NL 1014636 A NL1014636 A NL 1014636A NL 1014636 C2 NL1014636 C2 NL 1014636C2
- Authority
- NL
- Netherlands
- Prior art keywords
- vitamins
- rsi
- syndrome
- composition
- vitamin
- Prior art date
Links
- 235000019156 vitamin B Nutrition 0.000 title claims abstract description 10
- 239000011720 vitamin B Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 208000012514 Cumulative Trauma disease Diseases 0.000 title abstract description 29
- 206010038584 Repetitive strain injury Diseases 0.000 title abstract description 29
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 235000009492 vitamin B5 Nutrition 0.000 claims description 3
- 239000011675 vitamin B5 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 210000000707 wrist Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000011275 Epicondylitis Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 208000004678 Elbow Tendinopathy Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010039227 Rotator cuff syndrome Diseases 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- -1 tableting aids Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940053446 vitamin E d-alpha Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
- 1 - 5
Vitaminepreparaat
De onderhavige uitvinding heeft betrekking op een 10 vitaminepreparaat dat geschikt is voor het behandelen en voorkomen van RSI-syndroom.
In Nederland lijdt naar schatting 30 % van de beroepsbevolking aan RSI (Repetitive Strain Injury) en dreigen 400.000 beeldschermwerkers serieuze arbeidsproblemen te 15 krijgen t.g.v. het RSI-syndroom. Minstens 70% van beroepsmusici - wereldwijd - wordt ooit in zijn carrière belemmerd door klachten van houdings- en bewegingsapparaat. Ook andere beroepsgroepen, waaronder kappers, slagers, timmermannen, naaisters en metselaars krijgen RSI door herhaalde 20 hoge spierbelasting. Stress, werkdruk en een onregelmatige werktijden verhogen de risico's. Bij steeds meer mensen leidt RSI tot ziekteverzuim. Vrouwen (49%) hebben vaker klachten dan mannen (26%). Bij de beeldschermwerkers komen pijn in nek en schouders veel meer voor dan de 'muisarm' ; 25 die vooral op pijn en krachtverlies in arm en pols slaat. In de VS zijn de cijfers alarmerend. Tussen 1986 en 1993 groeide het aantal werknemers met klachten van de bovenste ledematen er met een factor drie. In Canada verdubbelde het aantal patiënten tussen 1986 en 1991. In Nederland krijgen 30 RSI en de werkdruk inmiddels de meeste aandacht in de discussie over arbeid en gezondheid. In het spraakgebruik is RSI inmiddels een ziekte. Maar in de officiële ziekteca-talogi (zoals de International Classification of Diseases, ICD) komt RSI niet voor. RSI is een paraplu waar veel al 35 lang bekende aandoeningen onder vallen. Het Amerikaanse Department of Health and Human Services concludeerde in een 1014636 - 2 - bibliografie uit 1995 dat al 165 ICD-codes zijn gebruikt in verband met RSI.
Typerend voor het RSI-syndroom zijn de volgende anamnese gegevens: klachten ontstaan vaak langzaam bij 5 belastende werkzaamheden; klachten verdwijnen meestal in rust en in het weekeinde. Er zijn vaak klachten zonder klinisch aantoonbare defecten. Klachten gaan niet vanzelf over als men gewoon doorwerkt, maar worden meestal erger bij doorwerken. De klachten zijn belastingafhankelijk en 10 wisselen soms van locatie en lichaamszijde. De meest voorkomende symptomen/subsyndromen van RSI zijn: hoofd pi jn/vermoeidheid; pijn en stijfheid in rug, nek, schouder (s) en tussen de schouderbladen; pijn en stijfheid in arm, pols en hand; onduidelijke diagnoses 'tennis- en/of 15 golferselleboog'; slijmbeursontstekingen aan schouder of elleboog; tintelingen / branderig /'raar'gevoel in (onder) arm, pols en hand; verlies van kracht in arm, pols en hand/zwaar gevoel in de armen; Carpaal Tunnel Syndroom.
20 Stadia
De (RSI) klachten kennen drie stadia, oplopend in ernst:
Stadixun 1: lichte pijn en/of stijfheid in nek/schouder of tussen de schouderbladen, vaak samen met 25 tintelingen, stijfheid of 'vreemd' gevoel in de (onder)ar-men/polsen/handen. De klachten treden op na langdurige belasting en gaan in rust meestal weer weg.
Stadivun 2. - de klachten treden steeds sneller op 30 en blijven steeds langer aanwezig na het stoppen van de belastende bezigheden. De relatie tussen inspanning en klachten wordt minder duidelijk. Bij andere bezigheden in het dagelijks leven treden de klachten vaker op. De klachten worden minder nauwkeurig te lokaliseren en er treedt 35 krachtsverlies in de handen en een 'zwaar' gevoel in de armen op.
1014636 4 - 3 -
Stadium 3: er is nu sprake van continue pijn die bij elke belastende bezigheid erger wordt, 's Nachts wordt de patiënt soms wakker van de klachten. Werken en andere dagelijkse bezigheden zijn nauwelijks uitvoerbaar zonder 5 klachten. Een veel beschreven symptoom is ook vermoeidheid.
Eén van de verklaringstheorieën voor het RSI-syndroom luidt als volgt:
De werkplek is oorzaak van een langdurige laagsta-tische spierbelasting in een ongunstige houding waardoor 10 rug-/nek-/schouderspieren continu aangespannen zijn. Er ontstaat een verstoorde energiehuishouding in de nek/schou-ders en beide armen, wat wil zeggen dat voedingsstoffen niet aangevoerd kunnen worden en dat afvalstoffen niet afgevoerd kunnen worden. Als de werker vervolgens van 15 zijn/haar kwetsbare armen een zeer eenzijdige hoog energetische belasting vraagt (denk aan typen, kassawerk of inpakwerk aan de lopende band), ontstaat op den duur schade aan spieren/pezen van de armen. Dit gaat vaak gepaard met bindweefselvorming (littekens). In veel gevallen ontstaat 20 op de overgang van stadium 2 naar stadium 3 een overgevoeligheid van de pijnbanen in het hele nek/schouder/arm/hand complex. Deze overgevoeligheid gaat via dwarsverbindingen in het ruggenmerg ook naar de andere lichaamszijde, hetgeen klachten aan de niet-dominante zijde kan verklaren. Stress 25 lijkt in veel gevallen een versterkende factor.
Gevonden is nu dat door het toedienen van een preparaat dat één of meer vitaminen B en eventueel andere vitaminen bevat aan personen die lijden aan het RSI-syndroom, de bij het RSI-syndroom optredende verschijnselen 30 aanzienlijk verlicht of zelfs geheel weggenomen worden.
Derhalve voorziet de uitvinding in het gebruik van een vitamine B of een preparaat dat één of meer vitaminen B bevat, voor het bereiden van een geneesmiddel voor het voorkomen of behandelen van het RSI-syndroom.
35 De uitvinding voorziet verder in een preparaat dat één of meer vitaminen B bevat in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.
1014636 4 - 4 -
Het preparaat volgens de uitvinding bevat in het bijzonder de vitaminen BI, B2, B3, B5, B6, B7 en B12 in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.
5 Personen die leden aan het RSI-syndroom en die het preparaat volgens de uitvinding oraal innamen, hadden na korte tijd aanzienlijk minder of in het geheel geen RSI-verschijnselen meer. Het preparaat van de uitvinding is ondermeer tegen de volgende met RSI verbonden aandoeningen 10 effectief gebleken: "rotator cuff syndroom", epicondylitis lateratis ("tenniselleboog") en epicondylitis medialis ("golferselleboog").
Het preparaat volgens de uitvinding kan elke geschikte farmaceutische toedieningsvorm hebben. Een 15 geschikte vorm voor orale toediening is bijvoorbeeld een tablet of een capsule.
Het preparaat kan naast de vitaminen B, de andere vitaminen en verdere werkzame stoffen de gebruikelijke farmaceutische hulpstoffen zoals dragers/verdunningsmiddelen, 20 vulstoffen, verdikkingsmiddelen, destintegreermiddelen, tabletteerhulpstoffen, kleur- en smaakstoffen etc. bevatten .
Voorbeeld 25 Een oraal preparaat met de in tabel 1 gegeven samenstelling van werkzame stoffen werd bereid en een- of tweemaal daags aan personen die leden aan het RSI-syndroom toegediend. De verkregen resultaten zijn samengevat in tabel 2.
30 1014636 - 5 -
Tabel 1 Samenstelling van de werkzame stoffen in het vitaminepreparaat
Eenheid mg Eenheid
Vitamine A Retinol 150 5 Vitamine BI thiaminemononi- 15 traat
Vitamine B2 . riboflavine 16
Vitamine B3 nicotinamide 25
Vitamine B5 calciumpantothe- 25 10 naat
Vitamine B6 pyridoxinehydro- 5,3 chloride
Vitamine B7 biotine 25
Vitamine B12 cyanocobalamine 1,7 15 Vitamine C ascorbinezuur 20
Vitamine D cholecaferol 1
Vitamine E D-alfa tocoferol 2
Inositol 5 p-aminoben- 40 20 zoëzuur
Calcium 215
Fosfor 200'
Kalium 640 25 Natrium. 125
Magnesium 35 IJzer 3
Mangaan 0,2
Zink 2 30 Jodium 2 5
Seleen 10
Koper 0,3 n 1 KQe - 6 -
Tabel 2 Resultaten ·
Proef- Man (M) Leef- Lengte RSI- Periode Resul- perso- Vrouw tijd periode stadium innemen taat nen (V) jaar RSI- middeel klach- (weken) ten (maanden) 5 Proef- V 22 3 1 31 Genezen persoon 1
Proef- M 50 5 1 121 Genezen persoon 10 2
Proef- M 42 36 3 32> Genezen persoon 3
Proef- M 29 24 3 2S> Aan- 15 persoon zien- 4 lijke verbe tering
Proef- V 28 24 3 221 Aan- persoon zien- 5 lijke verbe tering 20 Proef- M 50 40 3 22) Aan- persoon zien- 6 lijke verbe tering 1014636 behandeling beëindigd 25 21 behandeling wordt voortgezet
Claims (4)
1. Gebruik van een vitamine B of een preparaat dat 10 één of meer vitaminen B bevat, voor het bereiden van een geneesmiddel voor het voorkomen of behandelen van het RSI-syndroom.
2. Preparaat dat één of meer vitaminen B bevat in hoeveelheden die voldoende zijn voor het behandelen of 15 voorkomen van het RSI-syndroom.
3. Preparaat voor het behandelen of voorkomen van het RSI-syndroom, dat vitamines BI, B2, B3, B5, B6, B7 en B12 bevat in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.
4. Preparaat volgens conclusie 3, dat verder vitaminen A, C, D en E, inositol, p-aminobenzoëzuur, calcium, fosfor, kalium, natrium, magnesium, ijzer, mangaan, zink, jodium, seleen en koper bevat. 1 Π 1 3R
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1014636A NL1014636C2 (nl) | 2000-03-14 | 2000-03-14 | Vitaminepreparaat. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1014636 | 2000-03-14 | ||
| NL1014636A NL1014636C2 (nl) | 2000-03-14 | 2000-03-14 | Vitaminepreparaat. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL1014636A1 NL1014636A1 (nl) | 2001-09-17 |
| NL1014636C2 true NL1014636C2 (nl) | 2002-07-16 |
Family
ID=19770994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL1014636A NL1014636C2 (nl) | 2000-03-14 | 2000-03-14 | Vitaminepreparaat. |
Country Status (1)
| Country | Link |
|---|---|
| NL (1) | NL1014636C2 (nl) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0326034A2 (de) * | 1988-01-28 | 1989-08-02 | Peter Dr. Költringer | Kombinationspräparat zur Behandlung von Nervenzell-und Nervenfasererkrankungen und Verletzungen |
| DE4110087A1 (de) * | 1991-03-27 | 1992-10-01 | Fritz Dr Woerwag | Benfotiaminhaltiges arzneimittel und dessen verwendung |
| WO1994000135A1 (en) * | 1992-06-30 | 1994-01-06 | Shapiro Howard K | Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases |
| US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
| US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
| WO1997016079A1 (en) * | 1995-10-27 | 1997-05-09 | Societe Des Produits Nestle S.A. | Nutritional support of paediatric patients |
| WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
| WO2001091766A2 (en) * | 2000-06-01 | 2001-12-06 | Theralife, Inc. | Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
-
2000
- 2000-03-14 NL NL1014636A patent/NL1014636C2/nl not_active IP Right Cessation
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0326034A2 (de) * | 1988-01-28 | 1989-08-02 | Peter Dr. Költringer | Kombinationspräparat zur Behandlung von Nervenzell-und Nervenfasererkrankungen und Verletzungen |
| DE4110087A1 (de) * | 1991-03-27 | 1992-10-01 | Fritz Dr Woerwag | Benfotiaminhaltiges arzneimittel und dessen verwendung |
| WO1994000135A1 (en) * | 1992-06-30 | 1994-01-06 | Shapiro Howard K | Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases |
| US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
| US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
| WO1997016079A1 (en) * | 1995-10-27 | 1997-05-09 | Societe Des Produits Nestle S.A. | Nutritional support of paediatric patients |
| WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
| WO2001091766A2 (en) * | 2000-06-01 | 2001-12-06 | Theralife, Inc. | Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
Non-Patent Citations (3)
| Title |
|---|
| ALLEN-TAYLOR J.D.: "Silicon Vitamins", METRO, 28 January 1999 (1999-01-28) - 3 February 1999 (1999-02-03), pages 1 - 5, XP002190200, Retrieved from the Internet <URL:http://www.metroactive/com/papers/metro/01.28.99/slices-9904.html> [retrieved on 20020214] * |
| FOLKERS K ET AL: "SUCCESSFUL THERAPY WITH VITAMIN B-6 AND VITAMIN B-2 OF THE CARPAL TUNNEL SYNDROME AND NEED FOR DETERMINATION OF THE RDAS FOR VITAMINS B-6 AND B-2 FOR DISEASE STATES", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, pages 295 - 301, XP008000385, ISSN: 0077-8923 * |
| KASDAN M L ET AL: "CARPAL TUNNEL SYNDROME AND VITAMIN B-6", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 79, no. 3, 1987, pages 456 - 459, XP008000386, ISSN: 0032-1052 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NL1014636A1 (nl) | 2001-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cutter et al. | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial | |
| Jamshidovich | HEPTRAL IS USED IN LIVER DISEASES | |
| Messier et al. | Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study | |
| Brookoff et al. | Treating sickle cell pain like cancer pain | |
| Karbwang et al. | Pharmacokinetics of mefloquine alone or in combination with artesunate. | |
| Fenichel et al. | Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E | |
| Takala | Static muscular load, an increasing hazard in modern information technology | |
| Mock et al. | Current management of fatigue and anemia in patients with cancer | |
| HOCHBERG | Auranofin or D-penicillamine in the treatment of rheumatoid arthritis | |
| NL1014636C2 (nl) | Vitaminepreparaat. | |
| Wolter et al. | A clinical synthesis of falls intervention trials | |
| Margoles | Myofascial pain syndrome: Clinical evaluation and management of patients | |
| Binnick | Pityriasis rubra pilaris responding to aminonicotinamide | |
| AIRD | Trypan red therapy of amyotrophic lateral sclerosis: preliminary report | |
| Stone et al. | VITAMIN B AND E THERAPY IN TABES DORSALIS:(Preliminary Report on the Use of Wheat Germ Oil, Vitamin B Complex and Intraspinal Administration of Thiamin Chloride) | |
| Druckman | A case of subacute bacterial endocarditis with apparent cure | |
| Geier | Management approaches for improved patient outcomes. | |
| Shafiq et al. | Effect of Specific Stabilization Exercise Along with Muscle Relaxation Technique to Treat Lumbopelvic Pain During Pregnancy: Muscle Relaxation Technique to Treat Lumbopelvic Pain During Pregnancy | |
| Zizic et al. | The treatment of rheumatoid arthritis of the hand with pulsed electrical fields | |
| Daneshfard et al. | Fighting Fatigue in Military Forces | |
| Brinkhaus | Latest Publications You Should Not Miss | |
| Coulter | Occupational therapy in a private general hospital | |
| Freter et al. | Hip fractures and Alzheimer’s disease | |
| STRYKER et al. | Determination of macrocytic anemia as an aid in diagnosis of certain deficiency dermatoses | |
| Sevitt | Reflections on mortality and causes of death after injury and burns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AD1A | A request for search or an international type search has been filed | ||
| RD2N | Patents in respect of which a decision has been taken or a report has been made (novelty report) |
Effective date: 20020312 |
|
| PD2B | A search report has been drawn up | ||
| VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20081001 |